FLT3 and myelofibrosis: Fedratinib, an oral selective JAK2 inhibitor targeting FMS-like tyrosine kinase-3 (FLT-3), was approved by the Food and Drug Administration (FDA) in 2019 for the treatment of primary or secondary myelofibrosis, eight years after the introduction of ruxolitinib [116,122].